Week in Review: $1.4 Billion in China Life Science Deals and Financings

Deals and Financings

Trials and Approvals

• Shanghai's CARsgen presented positive early clinical data of a first-in-class CAR-Claudin18.2 T cell trial in patients with pancreatic and gastric cancer;
• Innovent Biologics of Suzhou announced that China's NMPA has approved an IND application for its anti-CD47 mAb in multiple tumor types;
• Shanghai's EpimAb Biotherapeutics filed US and China INDs simultaneously for a bispecific antibody that targets EGFR and cMET receptors.

Stock Symbols: (NSDQ: BCAC) (HK: 2552) (NSDQ: YI) (SHA: 600535) (SHA: 601607) (NSDQ: ZLAB) (NSDQ: NVCR)

Share this with colleagues:

Original Article: Week in Review: $1.4 Billion in China Life Science Deals and Financings

More From BioPortfolio on "Week in Review: $1.4 Billion in China Life Science Deals and Financings"